ZVRA

Business Context and Reporting Period

Zevra Therapeutics, Inc. (ZVRA) is a rare disease company focused on developing and commercializing therapies for diseases with limited treatment options. This Form 10-Q covers the quarterly period ended June 30, 2024. The company's portfolio includes the approved product OLPRUVA (for urea cycle disorders), the partnered product AZSTARYS (for ADHD), and clinical-stage candidates arimoclomol (for Niemann-Pick disease type C), celiprolol (for Vascular Ehlers-Danlos syndrome), and KP1077 (for idiopathic hypersomnia and narcolepsy).

On August 2, 2024, the FDA's Genetic Metabolic Diseases Advisory Committee voted favorably on the data supporting arimoclomol for NPC, with a PDUFA decision date set for September 21, 2024.

Key Financial Metrics

Liquidity: As of June 30, 2024, the company held $39.3 million in cash and cash equivalents and $10.0 million in securities at fair value. The company has a $100 million senior secured loan facility, of which $60 million was funded in April 2024.

Material Changes Versus Prior Period

• Revenue Decline: Revenue decreased by $4.0 million (47%) for the three months ended June 30, 2024, compared to the same period in 2023. This was primarily due to the absence of a $5.0 million net sales milestone recognized in Q2 2023 under the AZSTARYS License Agreement, partially offset by increased royalties and French Expanded Access Program (EAP) reimbursements.
• Increased Operating Expenses: Total operating expenses increased by $9.1 million to $23.1 million for the quarter. Research and Development (R&D) expenses rose $3.1 million, driven by the KP1077 Phase 2 study. Selling, General, and Administrative (SG&A) expenses increased $6.0 million due to headcount growth and commercial organization build-out.
• Inventory Obsolescence: Cost of product revenue increased significantly due to a $3.2 million charge for inventory obsolescence recognized in the quarter.
• Debt Restructuring: In April 2024, the company entered into a new $100 million credit agreement, funding $60 million to refinance existing indebtedness (including a Wells Fargo line of credit and a Nantahala note), which were repaid in full.
• Non-Cash Gains: The company recognized a $5.8 million gain from the fair value adjustment of warrant and Contingent Value Right (CVR) liabilities, reducing the net loss.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The company has incurred recurring operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern for at least one year from the filing date. Continued operations depend on generating revenue from approved products, obtaining regulatory approvals, or securing additional financing.
• Recent Financing (Subsequent Event): On August 12, 2024, the company closed an underwritten public offering of 10.6 million shares, raising approximately $64.5 million in net proceeds. Management believes these proceeds, combined with existing cash, will fund operations into the first quarter of 2027.
• Regulatory Milestones: The FDA has assigned a PDUFA date of September 21, 2024, for the arimoclomol NDA. The company is evaluating labeling comments received in August 2024.
• Commercialization: OLPRUVA commercialization in the U.S. is in early stages with de minimis revenue to date. Reimbursement coverage has improved from 55% to approximately 75% of U.S. covered lives since acquisition.
• Internal Controls: The company previously identified a material weakness regarding the accounting for warrants. Management concluded in Q2 2024 that this weakness has been remediated.

Key Facts for Investor Verification

• Ar imoclomol Approval Timeline: Verify the FDA's final decision on the arimoclomol NDA by the September 21, 2024 PDUFA date, as approval is critical for future revenue and potential Priority Review Voucher (PRV) value.
• Cash Runway: Confirm the sufficiency of the $64.5 million raised in August 2024 to fund operations through Q1 2027, considering the high burn rate and debt covenants.
• Debt Covenants: Review the terms of the $100 million credit agreement, specifically the minimum net product sales covenants and the requirement to maintain a $20 million minimum cash balance.
• OLPRUVA Commercial Traction: Monitor the growth of OLPRUVA sales and reimbursement rates, as current revenue is de minimis and the product is essential for meeting debt covenants.
• Inventory Valuation: Assess the $3.2 million inventory obsolescence charge and the remaining inventory balance ($10.2 million) for potential future write-downs.